Prof Marco Gobbi, Md - Università di Genova - Professor

Prof Marco Gobbi

Md

Università di Genova

Professor

Genova, Liguria | Italy

Main Specialties: Hematology

Additional Specialties: Hematology

Prof Marco Gobbi, Md - Università di Genova - Professor

Prof Marco Gobbi

Md

Introduction

Primary Affiliation: Università di Genova - Genova, Liguria , Italy

Specialties:

Additional Specialties:

Publications

52Publications

2520Reads

6Profile Views

421PubMed Central Citations

Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies.

Mycoses 2018 Sep 13;61(9):650-655. Epub 2018 Jun 13.

Infectious Diseases Unit, Department Health Sciences (DISSAL), Ospedale Policlinico San Martino - IRCCS per l'Oncologia, University of Genoa, Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/myc.12787DOI Listing
September 2018
28 Reads
1.805 Impact Factor

Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.

Hematol Oncol 2018 Apr 20;36(2):498-499. Epub 2017 Oct 20.

Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2484DOI Listing
April 2018
31 Reads
3.084 Impact Factor

Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.

Expert Rev Anticancer Ther 2016 09 22;16(9):897-8. Epub 2016 Jul 22.

a Chair of Hematology, Department of Medicine (DiMI) , University of Genoa, AOU, I.R.C.C.S. San Martino -IST , Genova , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2016.1212664DOI Listing
September 2016
18 Reads
2.250 Impact Factor

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.

Biomed Res Int 2015 22;2015:943096. Epub 2015 Oct 22.

Hematology Unit, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, 1600 Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/943096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633548PMC
August 2016
62 Reads

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.

Clin Cancer Res 2015 Sep 11;21(17):3934-45. Epub 2015 May 11.

Department of Hematology and Oncology, IRCCS AOU S. Martino-IST, Genoa, Italy. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3023DOI Listing
September 2015
46 Reads
8 Citations
8.722 Impact Factor

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Leuk Res 2015 Aug 27;39(8):866-73. Epub 2015 Apr 27.

Chair of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S Martino - IST, Genoa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.04.011DOI Listing
August 2015
49 Reads
1 Citation
2.351 Impact Factor

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

Ann Hematol 2014 Dec 4;93(12):2011-8. Epub 2014 Jul 4.

Division of Clinical Hematology and Division of Hematology and Hematopoietic Stem Cell Transplantation, IRCCS S Martino-IST, Viale Benedetto XV, N 6, 16132, Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2143-8DOI Listing
December 2014
64 Reads
2 Citations
2.634 Impact Factor

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.

Cancer Chemother Pharmacol 2014 Nov 13;74(5):1057-64. Epub 2014 Sep 13.

Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2583-9DOI Listing
November 2014
120 Reads
14 Citations
2.770 Impact Factor

Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Biol Blood Marrow Transplant 2014 Oct 5;20(10):1573-9. Epub 2014 Jun 5.

Division of Hematology and Marrow Transplantation, Istituto Ricerca Carattere Scientifico (IRCCS), San Martino Istituto Tumori (IST), Genova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.05.029DOI Listing
October 2014
73 Reads
48 Citations
3.404 Impact Factor

Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.

Leuk Res 2014 Jun 18;38(6):649-59. Epub 2014 Mar 18.

Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Hematology and Oncology, I.R.C.C.S. A.O.U. San Martino-IST, Genoa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.03.006DOI Listing
June 2014
19 Reads
12 Citations
2.351 Impact Factor

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

J Clin Oncol 2014 Jun 19;32(18):1919-26. Epub 2014 May 19.

Gail J. Roboz, Weill Cornell Medical College and the New York Presbyterian Hospital; Todd Rosenblat, Columbia University Medical Center, New York, NY; Martha Arellano, Winship Cancer Institute at Emory University; Scott R. Solomon, The Blood and Marrow Transplant Group of Georgia, Atlanta, GA; Jessica K. Altman, Francis J. Giles, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Casey O'Connell, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA; Marco Gobbi, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa, Italy; Pau Montesinos, Hospital Universitario y Politécnico La Fé, Valencia, Spain; Arnaud Pigneux, Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque, Pessac; Norbert Vey, L'Institut Paoli-Calmettes, Marseilles, France; Robert Hills, Cardiff University School of Medicine, Cardiff, United Kingdom; Tove Flem Jacobsen, Athos Gianella-Borradori, Øivind Foss, and Sylvia Vetrhus, Clavis Pharma ASA, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.8562DOI Listing
June 2014
81 Reads
26 Citations
18.430 Impact Factor

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Leuk Res 2013 Dec 23;37(12):1606-11. Epub 2013 Jul 23.

Department of Hematology and Oncology, IRCCS AOU S.Martino-IST, Genova, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.07.005DOI Listing
December 2013
45 Reads
3 Citations
2.351 Impact Factor

Chronic myeloid leukemia: reaching for the cure.

Curr Cancer Drug Targets 2013 Sep;13(7):709-10

Department of Internal Medicine University of Genoa V.le Benedetto XV 6, 16132 Genoa Italy.

View Article

Download full-text PDF

Source
September 2013
16 Reads
3.522 Impact Factor

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

Curr Cancer Drug Targets 2013 Sep;13(7):779-90

Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
September 2013
24 Reads
2 Citations
3.522 Impact Factor

New insights into biology of chronic myeloid leukemia: implications in therapy.

Curr Cancer Drug Targets 2013 Sep;13(7):711-23

Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
September 2013
12 Reads
2 Citations
3.522 Impact Factor

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Blood 2013 Aug 3;122(7):1243-55. Epub 2013 Jul 3.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-02-483511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744991PMC
August 2013
26 Reads
16 Citations
10.452 Impact Factor

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Curr Pharm Des 2013 ;19(4):734-44

Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171085PMC
July 2013
36 Reads
15 Citations
3.452 Impact Factor

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.

Autophagy 2013 Mar;9(3):410-2

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590260PMC
http://dx.doi.org/10.4161/auto.22866DOI Listing
March 2013
18 Reads
9 Citations
11.753 Impact Factor

Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.

Leuk Lymphoma 2013 Feb 5;54(2):342-52. Epub 2012 Sep 5.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.708752DOI Listing
February 2013
27 Reads
2 Citations

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

PLoS One 2011 Apr 18;6(4):e18925. Epub 2011 Apr 18.

Clinical Oncohaematology, Department of Internal Medicine, University of Genoa, Genoa, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018925PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078937PMC
April 2011
23 Reads
7 Citations
3.234 Impact Factor

Top co-authors

Antonia Cagnetta
Antonia Cagnetta

University of Genoa

16
Michele Cea
Michele Cea

University of Genoa

16
Maurizio Miglino
Maurizio Miglino

University of Genoa

15
Alessio Nencioni
Alessio Nencioni

University of Genoa

13
Franco Patrone
Franco Patrone

Department of Hematology and Oncology

13
Marino Clavio
Marino Clavio

University of Genova

12
Nicoletta Colombo
Nicoletta Colombo

European Institute of Oncology

9
Ivana Pierri
Ivana Pierri

IRCCS Azienda Ospedaliera Universitaria San Martino-IST

9
Filippo Ballerini
Filippo Ballerini

Clinic of Hematology

9
Fabio Guolo
Fabio Guolo

Clinic of Hematology

8